Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbott, BD, Centogene, Cochlear, Inmode.
LONDON – Owkin Inc. added a further $18 million to its series A, bringing the amount raised in the round to $70 million and equipping the company to push forward with its federated learning approach to applying artificial intelligence (AI) to the analysis of health data.
With the push for value-based care, health care players – from manufacturers, to providers, to payers – are looking for ways to improve patient quality while reducing the costs of care. Advanced technologies, including digital health and artificial intelligence (AI)-based tools, are a major part of the equation, but companies face several challenges and barriers to adoption. To that end, management consultancy has launched a new Health Tech website featuring a Health Tech Industry Accounting Guide and other helpful advice for health-tech companies.
TORONTO – Industry-led accelerator Next Generation Manufacturing Canada (NGen) has dipped into its CA$50 million (US$37 million) supercluster fund to help three Canadian companies beef up the nation’s supply of COVID-19 equipment and medical devices.
Evidation Health Inc. reported good news this week in the form of the close of $45 million in series D funding, with an eye toward the expansion of its research platform, Achievement, to include virtual health. B Capital Group led the round, with Mckesson Ventures and Section 32 joining, in addition to existing investors Revelation Partners, Rethink Impact and SV Health Investors.
Researchers working as part of the Quantitative Imaging Biomarkers Alliance (QIBA) have recently validated an open-source algorithm that can be used to measure blood flow using existing 3D ultrasound technology from major manufacturers. They published their results in the June 30, 2020, issue of Radiology.
LONDON – Digital health startup Gendius Ltd. is to take a lead role in an Astrazeneca plc initiative to improve diabetes care in the Gulf states, after signing an agreement to deploy its Intellin diabetes management system in the region.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aerus, Ancora Heart, Corelink, Endra Life Sciences, Illuminoss Medical, Kardium, Livsmed, Qure.ai, Seegene.
Conventional wisdom has it that recent expansions in coverage of telehealth will never be fully reversed. The addition of artificial intelligence (AI) into telehealth could solve several issues faced by doctors and hospitals. There is some concern, however, that the blending of AI and telehealth will industrialize the practice of medicine, dissuading patients from seeking critically needed care.
RSS
